Johnson & Johnson Pharmaceutical Research and Development: Difference between revisions
→Research Collabarative: Fixed misspelling in section heading. |
Rescuing 1 sources and tagging 0 as dead. #IABot (v1.2.7.1) |
||
| Line 5: | Line 5: | ||
==Research Collaborative== |
==Research Collaborative== |
||
In addition to internal research and development activities J&JPRD is also involved in publicly funded collaborative research projects, with other industrial and academic partners. One example in the area of [[Pre-clinical development|non-clinical]] safety assessment is the [[InnoMed PredTox]].<ref>{{Cite book| last1 = Mattes | first1 = William B.| chapter = Public Consortium Efforts in Toxicogenomics | doi = 10.1007/978-1-60327-048-9_11 | title = Essential Concepts in Toxicogenomics| editor1-last = Mendrick | editor1-first = Donna L.| editor2-last = Mattes | editor2-first = William B.| series = [[Methods in Molecular Biology]]| volume = 460 | pages = 221–238 | year = 2008 | isbn = 978-1-58829-638-2 | pmid = 18449490 | pmc = }}</ref><ref name="InnoMed PredTox official project website">{{cite web|url=http://www.innomed-predtox.com/consortium/members/|title=InnoMed PredTox Member Organizations|accessdate=2008-08-25}}</ref> The company is expanding its activities in joint research projects within the framework of the [[Innovative Medicines Initiative]] of [[EFPIA]] and the [[European Commission]].<ref name="IMI Call Topics 2008">{{cite web|url=http://imi.europa.eu/docs/calls01_en.zip|title=IMI Call Topics 2008|last=Innovative Medicines Initiative|work=IMI-GB-018v2-24042008-CallTopics.pdf|publisher=European Commission|accessdate=2008-08-25}} {{Dead link|date=October 2010|bot=H3llBot}}</ref> |
In addition to internal research and development activities J&JPRD is also involved in publicly funded collaborative research projects, with other industrial and academic partners. One example in the area of [[Pre-clinical development|non-clinical]] safety assessment is the [[InnoMed PredTox]].<ref>{{Cite book| last1 = Mattes | first1 = William B.| chapter = Public Consortium Efforts in Toxicogenomics | doi = 10.1007/978-1-60327-048-9_11 | title = Essential Concepts in Toxicogenomics| editor1-last = Mendrick | editor1-first = Donna L.| editor2-last = Mattes | editor2-first = William B.| series = [[Methods in Molecular Biology]]| volume = 460 | pages = 221–238 | year = 2008 | isbn = 978-1-58829-638-2 | pmid = 18449490 | pmc = }}</ref><ref name="InnoMed PredTox official project website">{{cite web|url=http://www.innomed-predtox.com/consortium/members/ |title=InnoMed PredTox Member Organizations |accessdate=2008-08-25 |deadurl=yes |archiveurl=https://web.archive.org/web/20080926214522/http://www.innomed-predtox.com/consortium/members/ |archivedate=2008-09-26 |df= }}</ref> The company is expanding its activities in joint research projects within the framework of the [[Innovative Medicines Initiative]] of [[EFPIA]] and the [[European Commission]].<ref name="IMI Call Topics 2008">{{cite web|url=http://imi.europa.eu/docs/calls01_en.zip|title=IMI Call Topics 2008|last=Innovative Medicines Initiative|work=IMI-GB-018v2-24042008-CallTopics.pdf|publisher=European Commission|accessdate=2008-08-25}} {{Dead link|date=October 2010|bot=H3llBot}}</ref> |
||
== References == |
== References == |
||
Revision as of 06:53, 2 January 2017
Johnson & Johnson Pharmaceutical Research and Development (J&JPRD) is a subsidiary of Johnson & Johnson that is responsible for discovering and developing pharmaceutical drugs. J&JPRD has research sites located in Raritan, New Jersey, Titusville, New Jersey, Spring House, Pennsylvania, La Jolla, California, Beerse, Belgium and Toledo, Spain.
J&JPRD was created in 2001 through the merging of various research organizations including McNeil Pharmaceuticals, Janssen Research Foundation, Three Dimensional Pharmaceuticals, and the R. W. Johnson Pharmaceutical Research Institute.
Research Collaborative
In addition to internal research and development activities J&JPRD is also involved in publicly funded collaborative research projects, with other industrial and academic partners. One example in the area of non-clinical safety assessment is the InnoMed PredTox.[1][2] The company is expanding its activities in joint research projects within the framework of the Innovative Medicines Initiative of EFPIA and the European Commission.[3]
References
- ^ Mattes, William B. (2008). "Public Consortium Efforts in Toxicogenomics". In Mendrick, Donna L.; Mattes, William B. (eds.). Essential Concepts in Toxicogenomics. Methods in Molecular Biology. Vol. 460. pp. 221–238. doi:10.1007/978-1-60327-048-9_11. ISBN 978-1-58829-638-2. PMID 18449490.
- ^ "InnoMed PredTox Member Organizations". Archived from the original on 2008-09-26. Retrieved 2008-08-25.
{{cite web}}: Unknown parameter|deadurl=ignored (|url-status=suggested) (help) - ^ Innovative Medicines Initiative. "IMI Call Topics 2008". IMI-GB-018v2-24042008-CallTopics.pdf. European Commission. Retrieved 2008-08-25. [dead link]
External links
 | This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it. |